Dermata Therapeutics, Inc. (DRMA) Stock Competitors & Peer Comparison
See (DRMA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DRMA | $1.19 | -0.83% | 811.1K | -0.29 | -$4.17 | N/A |
| NVO | $43.55 | -0.84% | 193.6B | 10.30 | $4.23 | +4.13% |
| VRTX | $453.17 | +0.60% | 115B | 26.89 | $16.85 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $614.73 | -0.04% | 63.3B | 15.01 | $40.95 | +0.59% |
| ARGX | $878.49 | -0.65% | 54.4B | 39.03 | $22.51 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $281.90 | -2.05% | 37.6B | 71.01 | $3.97 | N/A |
| RVMDW | $6.26 | -1.57% | 34.7B | N/A | N/A | N/A |
| RVMD | $156.58 | -2.17% | 33.3B | -22.02 | -$7.11 | N/A |
Stock Comparison
DRMA vs NVO Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, NVO has a market cap of 193.6B. Regarding current trading prices, DRMA is priced at $1.19, while NVO trades at $43.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas NVO's P/E ratio is 10.30. In terms of profitability, DRMA's ROE is -1.28%, compared to NVO's ROE of +0.66%. Regarding short-term risk, DRMA is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check NVO's competition here
DRMA vs VRTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, VRTX has a market cap of 115B. Regarding current trading prices, DRMA is priced at $1.19, while VRTX trades at $453.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas VRTX's P/E ratio is 26.89. In terms of profitability, DRMA's ROE is -1.28%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, DRMA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check VRTX's competition here
DRMA vs VRNA Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, DRMA is priced at $1.19, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas VRNA's P/E ratio is -102.80. In terms of profitability, DRMA's ROE is -1.28%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, DRMA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check VRNA's competition here
DRMA vs REGN Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, REGN has a market cap of 63.3B. Regarding current trading prices, DRMA is priced at $1.19, while REGN trades at $614.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas REGN's P/E ratio is 15.01. In terms of profitability, DRMA's ROE is -1.28%, compared to REGN's ROE of +0.14%. Regarding short-term risk, DRMA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check REGN's competition here
DRMA vs ARGX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ARGX has a market cap of 54.4B. Regarding current trading prices, DRMA is priced at $1.19, while ARGX trades at $878.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ARGX's P/E ratio is 39.03. In terms of profitability, DRMA's ROE is -1.28%, compared to ARGX's ROE of +0.37%. Regarding short-term risk, DRMA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check ARGX's competition here
DRMA vs SGEN Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, DRMA is priced at $1.19, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas SGEN's P/E ratio is -57.19. In terms of profitability, DRMA's ROE is -1.28%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, DRMA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check SGEN's competition here
DRMA vs ALNY Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ALNY has a market cap of 37.6B. Regarding current trading prices, DRMA is priced at $1.19, while ALNY trades at $281.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ALNY's P/E ratio is 71.01. In terms of profitability, DRMA's ROE is -1.28%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, DRMA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check ALNY's competition here
DRMA vs RVMDW Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, RVMDW has a market cap of 34.7B. Regarding current trading prices, DRMA is priced at $1.19, while RVMDW trades at $6.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas RVMDW's P/E ratio is N/A. In terms of profitability, DRMA's ROE is -1.28%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, DRMA is less volatile compared to RVMDW. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check RVMDW's competition here
DRMA vs RVMD Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, RVMD has a market cap of 33.3B. Regarding current trading prices, DRMA is priced at $1.19, while RVMD trades at $156.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas RVMD's P/E ratio is -22.02. In terms of profitability, DRMA's ROE is -1.28%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, DRMA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check RVMD's competition here
DRMA vs RPRX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, RPRX has a market cap of 23.3B. Regarding current trading prices, DRMA is priced at $1.19, while RPRX trades at $54.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas RPRX's P/E ratio is 28.53. In terms of profitability, DRMA's ROE is -1.28%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, DRMA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check RPRX's competition here
DRMA vs UTHR Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, DRMA is priced at $1.19, while UTHR trades at $548.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas UTHR's P/E ratio is 20.29. In terms of profitability, DRMA's ROE is -1.28%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, DRMA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check UTHR's competition here
DRMA vs BNTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, BNTX has a market cap of 22.6B. Regarding current trading prices, DRMA is priced at $1.19, while BNTX trades at $89.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas BNTX's P/E ratio is -15.30. In terms of profitability, DRMA's ROE is -1.28%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, DRMA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check BNTX's competition here
DRMA vs MRNA Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, MRNA has a market cap of 22B. Regarding current trading prices, DRMA is priced at $1.19, while MRNA trades at $55.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas MRNA's P/E ratio is -6.80. In terms of profitability, DRMA's ROE is -1.28%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, DRMA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check MRNA's competition here
DRMA vs ROIV Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ROIV has a market cap of 21.9B. Regarding current trading prices, DRMA is priced at $1.19, while ROIV trades at $30.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ROIV's P/E ratio is -56.31. In terms of profitability, DRMA's ROE is -1.28%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, DRMA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check ROIV's competition here
DRMA vs INSM Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, INSM has a market cap of 20.7B. Regarding current trading prices, DRMA is priced at $1.19, while INSM trades at $95.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas INSM's P/E ratio is -16.58. In terms of profitability, DRMA's ROE is -1.28%, compared to INSM's ROE of -1.30%. Regarding short-term risk, DRMA is less volatile compared to INSM. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check INSM's competition here
DRMA vs BGNE Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, DRMA is priced at $1.19, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas BGNE's P/E ratio is -22.55. In terms of profitability, DRMA's ROE is -1.28%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, DRMA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check BGNE's competition here
DRMA vs INCY Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, INCY has a market cap of 19.9B. Regarding current trading prices, DRMA is priced at $1.19, while INCY trades at $99.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas INCY's P/E ratio is 14.09. In terms of profitability, DRMA's ROE is -1.28%, compared to INCY's ROE of +0.29%. Regarding short-term risk, DRMA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check INCY's competition here
DRMA vs DNA-WT Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, DRMA is priced at $1.19, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, DRMA's ROE is -1.28%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, DRMA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check DNA-WT's competition here
DRMA vs NBIX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, NBIX has a market cap of 15.7B. Regarding current trading prices, DRMA is priced at $1.19, while NBIX trades at $156.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas NBIX's P/E ratio is 24.06. In terms of profitability, DRMA's ROE is -1.28%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, DRMA is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check NBIX's competition here
DRMA vs GMAB Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, GMAB has a market cap of 15.2B. Regarding current trading prices, DRMA is priced at $1.19, while GMAB trades at $24.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas GMAB's P/E ratio is 18.89. In terms of profitability, DRMA's ROE is -1.28%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, DRMA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check GMAB's competition here
DRMA vs ASND Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ASND has a market cap of 14.4B. Regarding current trading prices, DRMA is priced at $1.19, while ASND trades at $231.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ASND's P/E ratio is 26.48. In terms of profitability, DRMA's ROE is -1.28%, compared to ASND's ROE of -56.42%. Regarding short-term risk, DRMA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check ASND's competition here
DRMA vs JAZZ Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, JAZZ has a market cap of 14.3B. Regarding current trading prices, DRMA is priced at $1.19, while JAZZ trades at $226.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas JAZZ's P/E ratio is 1890.67. In terms of profitability, DRMA's ROE is -1.28%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, DRMA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check JAZZ's competition here
DRMA vs EXEL Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, EXEL has a market cap of 13.1B. Regarding current trading prices, DRMA is priced at $1.19, while EXEL trades at $52.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas EXEL's P/E ratio is 17.25. In terms of profitability, DRMA's ROE is -1.28%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, DRMA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check EXEL's competition here
DRMA vs BBIO Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, DRMA is priced at $1.19, while BBIO trades at $66.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas BBIO's P/E ratio is -17.82. In terms of profitability, DRMA's ROE is -1.28%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, DRMA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check BBIO's competition here
DRMA vs AXSM Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, AXSM has a market cap of 13B. Regarding current trading prices, DRMA is priced at $1.19, while AXSM trades at $251.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas AXSM's P/E ratio is -67.72. In terms of profitability, DRMA's ROE is -1.28%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, DRMA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check AXSM's competition here
DRMA vs KRTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, DRMA is priced at $1.19, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas KRTX's P/E ratio is -28.09. In terms of profitability, DRMA's ROE is -1.28%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, DRMA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check KRTX's competition here
DRMA vs IONS Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, IONS has a market cap of 12.1B. Regarding current trading prices, DRMA is priced at $1.19, while IONS trades at $73.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas IONS's P/E ratio is -36.36. In terms of profitability, DRMA's ROE is -1.28%, compared to IONS's ROE of -0.59%. Regarding short-term risk, DRMA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check IONS's competition here
DRMA vs MDGL Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, MDGL has a market cap of 11.6B. Regarding current trading prices, DRMA is priced at $1.19, while MDGL trades at $501.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas MDGL's P/E ratio is -37.10. In terms of profitability, DRMA's ROE is -1.28%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, DRMA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check MDGL's competition here
DRMA vs RNAM Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, DRMA is priced at $1.19, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas RNAM's P/E ratio is -17.39. In terms of profitability, DRMA's ROE is -1.28%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, DRMA is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check RNAM's competition here
DRMA vs ARWR Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ARWR has a market cap of 10.8B. Regarding current trading prices, DRMA is priced at $1.19, while ARWR trades at $76.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ARWR's P/E ratio is -33.72. In terms of profitability, DRMA's ROE is -1.28%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, DRMA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check ARWR's competition here
DRMA vs SMMT Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, SMMT has a market cap of 10.8B. Regarding current trading prices, DRMA is priced at $1.19, while SMMT trades at $13.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas SMMT's P/E ratio is -8.73. In terms of profitability, DRMA's ROE is -1.28%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, DRMA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check SMMT's competition here
DRMA vs BMRN Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, BMRN has a market cap of 10.7B. Regarding current trading prices, DRMA is priced at $1.19, while BMRN trades at $55.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas BMRN's P/E ratio is 39.67. In terms of profitability, DRMA's ROE is -1.28%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, DRMA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check BMRN's competition here
DRMA vs RXDX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, DRMA is priced at $1.19, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas RXDX's P/E ratio is -56.47. In terms of profitability, DRMA's ROE is -1.28%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, DRMA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check RXDX's competition here
DRMA vs KRYS Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, KRYS has a market cap of 9.5B. Regarding current trading prices, DRMA is priced at $1.19, while KRYS trades at $323.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas KRYS's P/E ratio is 43.23. In terms of profitability, DRMA's ROE is -1.28%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, DRMA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check KRYS's competition here
DRMA vs CYTK Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CYTK has a market cap of 9.4B. Regarding current trading prices, DRMA is priced at $1.19, while CYTK trades at $75.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CYTK's P/E ratio is -10.98. In terms of profitability, DRMA's ROE is -1.28%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, DRMA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check CYTK's competition here
DRMA vs NUVL Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, DRMA is priced at $1.19, while NUVL trades at $123.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas NUVL's P/E ratio is -20.36. In terms of profitability, DRMA's ROE is -1.28%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, DRMA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check NUVL's competition here
DRMA vs CORT Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CORT has a market cap of 9B. Regarding current trading prices, DRMA is priced at $1.19, while CORT trades at $83.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CORT's P/E ratio is 239.17. In terms of profitability, DRMA's ROE is -1.28%, compared to CORT's ROE of +0.08%. Regarding short-term risk, DRMA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CORT's competition here
DRMA vs TECH Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, TECH has a market cap of 8.8B. Regarding current trading prices, DRMA is priced at $1.19, while TECH trades at $56.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas TECH's P/E ratio is 80.04. In terms of profitability, DRMA's ROE is -1.28%, compared to TECH's ROE of +0.05%. Regarding short-term risk, DRMA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check TECH's competition here
DRMA vs IMGN Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, DRMA is priced at $1.19, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas IMGN's P/E ratio is -111.55. In terms of profitability, DRMA's ROE is -1.28%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, DRMA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check IMGN's competition here
DRMA vs BPMC Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, DRMA is priced at $1.19, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas BPMC's P/E ratio is -51.58. In terms of profitability, DRMA's ROE is -1.28%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, DRMA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check BPMC's competition here
DRMA vs HALO Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, HALO has a market cap of 8.3B. Regarding current trading prices, DRMA is priced at $1.19, while HALO trades at $69.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas HALO's P/E ratio is 24.44. In terms of profitability, DRMA's ROE is -1.28%, compared to HALO's ROE of +1.26%. Regarding short-term risk, DRMA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check HALO's competition here
DRMA vs CERE Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, DRMA is priced at $1.19, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CERE's P/E ratio is -16.47. In terms of profitability, DRMA's ROE is -1.28%, compared to CERE's ROE of -0.72%. Regarding short-term risk, DRMA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CERE's competition here
DRMA vs TGTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, TGTX has a market cap of 7.7B. Regarding current trading prices, DRMA is priced at $1.19, while TGTX trades at $50.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas TGTX's P/E ratio is 17.67. In terms of profitability, DRMA's ROE is -1.28%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, DRMA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check TGTX's competition here
DRMA vs MTSR Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, DRMA is priced at $1.19, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas MTSR's P/E ratio is -23.58. In terms of profitability, DRMA's ROE is -1.28%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, DRMA is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check MTSR's competition here
DRMA vs ALKS Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ALKS has a market cap of 7.3B. Regarding current trading prices, DRMA is priced at $1.19, while ALKS trades at $44.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ALKS's P/E ratio is 48.99. In terms of profitability, DRMA's ROE is -1.28%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, DRMA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check ALKS's competition here
DRMA vs KYMR Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, KYMR has a market cap of 7.2B. Regarding current trading prices, DRMA is priced at $1.19, while KYMR trades at $87.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas KYMR's P/E ratio is -24.42. In terms of profitability, DRMA's ROE is -1.28%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, DRMA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check KYMR's competition here
DRMA vs PCVX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, PCVX has a market cap of 7.1B. Regarding current trading prices, DRMA is priced at $1.19, while PCVX trades at $49.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas PCVX's P/E ratio is -7.16. In terms of profitability, DRMA's ROE is -1.28%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, DRMA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check PCVX's competition here
DRMA vs PTGX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, PTGX has a market cap of 7.1B. Regarding current trading prices, DRMA is priced at $1.19, while PTGX trades at $110.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas PTGX's P/E ratio is -61.13. In terms of profitability, DRMA's ROE is -1.28%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, DRMA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check PTGX's competition here
DRMA vs IBRX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, IBRX has a market cap of 7B. Regarding current trading prices, DRMA is priced at $1.19, while IBRX trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas IBRX's P/E ratio is -7.91. In terms of profitability, DRMA's ROE is -1.28%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, DRMA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check IBRX's competition here
DRMA vs IMVT Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, DRMA is priced at $1.19, while IMVT trades at $33.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas IMVT's P/E ratio is -12.13. In terms of profitability, DRMA's ROE is -1.28%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, DRMA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check IMVT's competition here
DRMA vs MRUS Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, DRMA is priced at $1.19, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas MRUS's P/E ratio is -17.05. In terms of profitability, DRMA's ROE is -1.28%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, DRMA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check MRUS's competition here
DRMA vs ACLX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, DRMA is priced at $1.19, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ACLX's P/E ratio is -28.27. In terms of profitability, DRMA's ROE is -1.28%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, DRMA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check ACLX's competition here
DRMA vs RETA Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, DRMA is priced at $1.19, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas RETA's P/E ratio is -66.29. In terms of profitability, DRMA's ROE is -1.28%, compared to RETA's ROE of +0.47%. Regarding short-term risk, DRMA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check RETA's competition here
DRMA vs ABVX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ABVX has a market cap of 6.4B. Regarding current trading prices, DRMA is priced at $1.19, while ABVX trades at $97.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ABVX's P/E ratio is -18.33. In terms of profitability, DRMA's ROE is -1.28%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, DRMA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check ABVX's competition here
DRMA vs LEGN Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, LEGN has a market cap of 6.2B. Regarding current trading prices, DRMA is priced at $1.19, while LEGN trades at $33.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas LEGN's P/E ratio is -24.19. In terms of profitability, DRMA's ROE is -1.28%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, DRMA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check LEGN's competition here
DRMA vs RYTM Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, DRMA is priced at $1.19, while RYTM trades at $89.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas RYTM's P/E ratio is -28.70. In terms of profitability, DRMA's ROE is -1.28%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, DRMA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check RYTM's competition here
DRMA vs CNTA Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CNTA has a market cap of 6.2B. Regarding current trading prices, DRMA is priced at $1.19, while CNTA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CNTA's P/E ratio is -22.33. In terms of profitability, DRMA's ROE is -1.28%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, DRMA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CNTA's competition here
DRMA vs PTCT Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, DRMA is priced at $1.19, while PTCT trades at $73.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas PTCT's P/E ratio is -28.85. In terms of profitability, DRMA's ROE is -1.28%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, DRMA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check PTCT's competition here
DRMA vs LQDA Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, LQDA has a market cap of 6B. Regarding current trading prices, DRMA is priced at $1.19, while LQDA trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas LQDA's P/E ratio is 400.06. In terms of profitability, DRMA's ROE is -1.28%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, DRMA is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check LQDA's competition here
DRMA vs COGT Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, COGT has a market cap of 5.7B. Regarding current trading prices, DRMA is priced at $1.19, while COGT trades at $33.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas COGT's P/E ratio is -15.24. In terms of profitability, DRMA's ROE is -1.28%, compared to COGT's ROE of -0.83%. Regarding short-term risk, DRMA is less volatile compared to COGT. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check COGT's competition here
DRMA vs CDTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, DRMA is priced at $1.19, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CDTX's P/E ratio is -19.77. In terms of profitability, DRMA's ROE is -1.28%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, DRMA is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CDTX's competition here
DRMA vs BLTE Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, BLTE has a market cap of 5.5B. Regarding current trading prices, DRMA is priced at $1.19, while BLTE trades at $138.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas BLTE's P/E ratio is -54.41. In terms of profitability, DRMA's ROE is -1.28%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, DRMA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check BLTE's competition here
DRMA vs ABCM Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, DRMA is priced at $1.19, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, DRMA's ROE is -1.28%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, DRMA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check ABCM's competition here
DRMA vs ISEE Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, DRMA is priced at $1.19, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ISEE's P/E ratio is -22.44. In terms of profitability, DRMA's ROE is -1.28%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, DRMA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check ISEE's competition here
DRMA vs SRRK Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, SRRK has a market cap of 5.5B. Regarding current trading prices, DRMA is priced at $1.19, while SRRK trades at $45.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas SRRK's P/E ratio is -13.21. In terms of profitability, DRMA's ROE is -1.28%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, DRMA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check SRRK's competition here
DRMA vs PRAX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, PRAX has a market cap of 5.4B. Regarding current trading prices, DRMA is priced at $1.19, while PRAX trades at $257.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas PRAX's P/E ratio is -19.20. In terms of profitability, DRMA's ROE is -1.28%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, DRMA is less volatile compared to PRAX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check PRAX's competition here
DRMA vs CGON Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CGON has a market cap of 5.3B. Regarding current trading prices, DRMA is priced at $1.19, while CGON trades at $60.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CGON's P/E ratio is -25.76. In terms of profitability, DRMA's ROE is -1.28%, compared to CGON's ROE of -0.23%. Regarding short-term risk, DRMA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CGON's competition here
DRMA vs FBIOX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, DRMA is priced at $1.19, while FBIOX trades at $25.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas FBIOX's P/E ratio is N/A. In terms of profitability, DRMA's ROE is -1.28%, compared to FBIOX's ROE of N/A. Regarding short-term risk, DRMA is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check FBIOX's competition here
DRMA vs APGE Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, APGE has a market cap of 5.3B. Regarding current trading prices, DRMA is priced at $1.19, while APGE trades at $85.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas APGE's P/E ratio is -19.69. In terms of profitability, DRMA's ROE is -1.28%, compared to APGE's ROE of -0.33%. Regarding short-term risk, DRMA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check APGE's competition here
DRMA vs APLS Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, DRMA is priced at $1.19, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas APLS's P/E ratio is 38.35. In terms of profitability, DRMA's ROE is -1.28%, compared to APLS's ROE of +0.40%. Regarding short-term risk, DRMA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check APLS's competition here
DRMA vs LGND Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, LGND has a market cap of 5.1B. Regarding current trading prices, DRMA is priced at $1.19, while LGND trades at $255.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas LGND's P/E ratio is 33.24. In terms of profitability, DRMA's ROE is -1.28%, compared to LGND's ROE of +0.16%. Regarding short-term risk, DRMA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check LGND's competition here
DRMA vs MIRM Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, DRMA is priced at $1.19, while MIRM trades at $101.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas MIRM's P/E ratio is -7.47. In terms of profitability, DRMA's ROE is -1.28%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, DRMA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check MIRM's competition here
DRMA vs CAI Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, DRMA is priced at $1.19, while CAI trades at $17.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CAI's P/E ratio is -6.51. In terms of profitability, DRMA's ROE is -1.28%, compared to CAI's ROE of +0.06%. Regarding short-term risk, DRMA is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CAI's competition here
DRMA vs SYRE Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, SYRE has a market cap of 5B. Regarding current trading prices, DRMA is priced at $1.19, while SYRE trades at $83.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas SYRE's P/E ratio is -39.34. In terms of profitability, DRMA's ROE is -1.28%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, DRMA is less volatile compared to SYRE. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check SYRE's competition here
DRMA vs CRSP Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CRSP has a market cap of 5B. Regarding current trading prices, DRMA is priced at $1.19, while CRSP trades at $52.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CRSP's P/E ratio is -8.43. In terms of profitability, DRMA's ROE is -1.28%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, DRMA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check CRSP's competition here
DRMA vs TVTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, TVTX has a market cap of 5B. Regarding current trading prices, DRMA is priced at $1.19, while TVTX trades at $53.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas TVTX's P/E ratio is -106.76. In terms of profitability, DRMA's ROE is -1.28%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, DRMA is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check TVTX's competition here
DRMA vs TERN Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, DRMA is priced at $1.19, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas TERN's P/E ratio is -51.41. In terms of profitability, DRMA's ROE is -1.28%, compared to TERN's ROE of -0.20%. Regarding short-term risk, DRMA is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check TERN's competition here
DRMA vs FOLD Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, DRMA is priced at $1.19, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas FOLD's P/E ratio is -161.00. In terms of profitability, DRMA's ROE is -1.28%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, DRMA is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check FOLD's competition here
DRMA vs AKRO Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, DRMA is priced at $1.19, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas AKRO's P/E ratio is -14.57. In terms of profitability, DRMA's ROE is -1.28%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, DRMA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check AKRO's competition here
DRMA vs ALPN Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, DRMA is priced at $1.19, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ALPN's P/E ratio is -101.52. In terms of profitability, DRMA's ROE is -1.28%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, DRMA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check ALPN's competition here
DRMA vs CELC Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CELC has a market cap of 4.3B. Regarding current trading prices, DRMA is priced at $1.19, while CELC trades at $87.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CELC's P/E ratio is -22.39. In terms of profitability, DRMA's ROE is -1.28%, compared to CELC's ROE of -2.45%. Regarding short-term risk, DRMA is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CELC's competition here
DRMA vs OPT Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, DRMA is priced at $1.19, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas OPT's P/E ratio is -1.52. In terms of profitability, DRMA's ROE is -1.28%, compared to OPT's ROE of +1.09%. Regarding short-term risk, DRMA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check OPT's competition here
DRMA vs ERAS Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, DRMA is priced at $1.19, while ERAS trades at $13.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ERAS's P/E ratio is -14.39. In terms of profitability, DRMA's ROE is -1.28%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, DRMA is less volatile compared to ERAS. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check ERAS's competition here
DRMA vs MRTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, DRMA is priced at $1.19, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas MRTX's P/E ratio is -4.82. In terms of profitability, DRMA's ROE is -1.28%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, DRMA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check MRTX's competition here
DRMA vs XENE Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, XENE has a market cap of 4.1B. Regarding current trading prices, DRMA is priced at $1.19, while XENE trades at $51.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas XENE's P/E ratio is -11.06. In terms of profitability, DRMA's ROE is -1.28%, compared to XENE's ROE of -0.49%. Regarding short-term risk, DRMA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check XENE's competition here
DRMA vs VCYT Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, VCYT has a market cap of 4.1B. Regarding current trading prices, DRMA is priced at $1.19, while VCYT trades at $50.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas VCYT's P/E ratio is 47.15. In terms of profitability, DRMA's ROE is -1.28%, compared to VCYT's ROE of +0.07%. Regarding short-term risk, DRMA is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check VCYT's competition here
DRMA vs TNGX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, DRMA is priced at $1.19, while TNGX trades at $32.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas TNGX's P/E ratio is -38.75. In terms of profitability, DRMA's ROE is -1.28%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, DRMA is less volatile compared to TNGX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check TNGX's competition here
DRMA vs KNSA Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, KNSA has a market cap of 3.9B. Regarding current trading prices, DRMA is priced at $1.19, while KNSA trades at $52.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas KNSA's P/E ratio is 57.47. In terms of profitability, DRMA's ROE is -1.28%, compared to KNSA's ROE of +0.13%. Regarding short-term risk, DRMA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check KNSA's competition here
DRMA vs CPRX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CPRX has a market cap of 3.8B. Regarding current trading prices, DRMA is priced at $1.19, while CPRX trades at $31.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CPRX's P/E ratio is 18.12. In terms of profitability, DRMA's ROE is -1.28%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, DRMA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CPRX's competition here
DRMA vs MANE Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, MANE has a market cap of 3.8B. Regarding current trading prices, DRMA is priced at $1.19, while MANE trades at $90.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas MANE's P/E ratio is -34.45. In terms of profitability, DRMA's ROE is -1.28%, compared to MANE's ROE of -0.95%. Regarding short-term risk, DRMA is less volatile compared to MANE. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check MANE's competition here
DRMA vs RYZB Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, DRMA is priced at $1.19, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas RYZB's P/E ratio is -57.86. In terms of profitability, DRMA's ROE is -1.28%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, DRMA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check RYZB's competition here
DRMA vs CBAY Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, DRMA is priced at $1.19, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CBAY's P/E ratio is -32.81. In terms of profitability, DRMA's ROE is -1.28%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, DRMA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check CBAY's competition here
DRMA vs CRNX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, CRNX has a market cap of 3.7B. Regarding current trading prices, DRMA is priced at $1.19, while CRNX trades at $35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas CRNX's P/E ratio is -6.81. In terms of profitability, DRMA's ROE is -1.28%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, DRMA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check CRNX's competition here
DRMA vs EWTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, EWTX has a market cap of 3.7B. Regarding current trading prices, DRMA is priced at $1.19, while EWTX trades at $33.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas EWTX's P/E ratio is -20.21. In terms of profitability, DRMA's ROE is -1.28%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, DRMA is less volatile compared to EWTX. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check EWTX's competition here
DRMA vs ACAD Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, DRMA is priced at $1.19, while ACAD trades at $20.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas ACAD's P/E ratio is 9.48. In terms of profitability, DRMA's ROE is -1.28%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, DRMA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check ACAD's competition here
DRMA vs NAMSW Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, DRMA is priced at $1.19, while NAMSW trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas NAMSW's P/E ratio is N/A. In terms of profitability, DRMA's ROE is -1.28%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, DRMA is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check NAMSW's competition here
DRMA vs SWTX Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, DRMA is priced at $1.19, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas SWTX's P/E ratio is -13.78. In terms of profitability, DRMA's ROE is -1.28%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, DRMA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for DRMA.Check SWTX's competition here
DRMA vs NAMS Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, DRMA is priced at $1.19, while NAMS trades at $30.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas NAMS's P/E ratio is -16.96. In terms of profitability, DRMA's ROE is -1.28%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, DRMA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check NAMS's competition here
DRMA vs DNLI Comparison June 2026
DRMA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DRMA stands at 811.1K. In comparison, DNLI has a market cap of 3.5B. Regarding current trading prices, DRMA is priced at $1.19, while DNLI trades at $21.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DRMA currently has a P/E ratio of -0.29, whereas DNLI's P/E ratio is -7.61. In terms of profitability, DRMA's ROE is -1.28%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, DRMA is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for DRMA.Check DNLI's competition here